The YhhN protein of Legionella pneumophila is a Lysoplasmalogenase  by Jurkowitz, Marianne S. et al.
Biochimica et Biophysica Acta 1848 (2015) 742–751
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamemThe YhhN protein of Legionella pneumophila is a LysoplasmalogenaseMarianne S. Jurkowitz a,⁎, Aalapi Patel a, Lai-Chu Wu a,b, Annalise Krautwater a,
Douglas R. Pfeiffer a, Charles E. Bell a,c
a Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, OH 43210, USA
b The Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
c Department of Chemistry and Biochemistry, The Ohio State University, Columbus, OH 43210, USAAbbreviations:AA, arachidonic acid; ADH, alcohol deh
albumin;DHA, docosahexaenoic acid; DTT, dithiothreitol;
HDL, high-density lipoproteins; His, histidine; NADH, nico
KPi, potassium phosphate buffer; PBS, phosphate-bu
independent phospholipase A2; SDS, sodiumdodecyl sulfa
protein 86B
⁎ Corresponding author at: Department of Molecular a
Neil Avenue, Room 310 Hamilton Hall,Ohio State Unive
State University, Columbus, OH 43210, USA. Tel.: +1 614
E-mail address: jurkowitz.1@osu.edu (M.S. Jurkowitz)
http://dx.doi.org/10.1016/j.bbamem.2014.11.011
0005-2736/Published by Elsevier B.V.a b s t r a c ta r t i c l e i n f oArticle history:
Received 17 June 2014
Received in revised form 25 October 2014
Accepted 10 November 2014
Available online 16 November 2014
Keywords:
Plasmalogen/lysoplasmalogen
Lysoplasmalogenase
YhhN gene Lpg1991
Vinyl ether bond
Legionella pneumophila
LysophospholipaseLysoplasmalogenase catalyzes hydrolytic cleavage of the vinyl-ether bond of lysoplasmalogen to yield fatty alde-
hyde and glycerophospho-ethanolamine or glycerophospho-choline. We recently puriﬁed lysoplasmalogenase
from rat liver microsomes and identiﬁed the protein as TMEM86B, an integral membrane protein that is a mem-
ber of the YhhN family found in numerous species of eukaryotes and bacteria. To test the hypothesis that bacte-
rial YhhN proteins also function as lysoplasmalogenase enzymes, we cloned the Lpg1991 gene of Legionella
pneumophila,which encodes a 216 amino acid YhhN protein (LpYhhN), and expressed it in Escherichia coli as a
C-terminal-GFP-His8-fusion. Membranes were solubilized and the fusion protein was puriﬁed by nickel-
afﬁnity chromatography, cleaved with Tobacco Etch Virus protease, and subjected to a reverse nickel column
to purify the un-tagged LpYhhN. Both the fusion protein and un-tagged LpYhhN exhibit robust
lysoplasmalogenase activity, cleaving the vinyl-ether bond of lysoplasmalogen with a Vmax of 12 µmol/
min/mg protein and a Km of 45 μM. LpYhhN has no activity on diradyl plasmalogen, 1-alkenyl-glycerol,
and monoacylglycerophospho-ethanolamine or monoacylglycerophospho-choline; the pH optimum is
6.5–7.0. These properties are very similar to mammalian TMEM86B. Sequence analysis suggests that
YhhN proteins contain eight transmembrane helices, an N-in/C-in topology, and about 5 highly conserved
amino acid residues that may form an active site. This work is the ﬁrst to demonstrate a function for a bacterial
YhhNprotein, as a vinyl ether bondhydrolase speciﬁc for lysoplasmalogen. Since L. pneumophila does not contain
endogenous plasmalogens, we hypothesize that LpYhhN may serve to protect the bacterium from lysis by
lysoplasmalogen derived from plasmalogens of the host.
Published by Elsevier B.V.1. Introduction
Plasmalogens (1-alk-1′-enyl- 2- acyl-sn-glycero-3-phospho-ethanol-
amine or –choline) are glycerophospholipids that differ from the com-
mon diacylglycerophospholipids in having a vinyl-ether linkage at sn-
1 [1]. These membrane lipids are widely distributed in vertebrate and
invertebrate animal species [2] and in anaerobic bacteria, but absent
in aerobic and facultative anaerobic bacteria, fungi, and plants [1]. In
mammals, plasmalogens constitute 4–32% of the total phospholipidydrogenase; BSA, bovine serum
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.mass, depending on the cell and tissue type. They are particularly high
in neural tissue, heart, lung, and circulating immune cells.
The presence of the vinyl-ether bond confers unique physical and
chemical properties to plasmalogens and to the membranes that contain
them [3]. Plasmalogens pack more closely with one another, which leads
to decreases in membrane ﬂuidity and passive ion permeability [4].
Plasmalogens also have a higher propensity to form an inverse hexagonal
phase, which is important for membrane fusion events [5]. As the vinyl
ether bond is particularly sensitive to non-enzymatic oxidative cleavage
[6,7], plasmalogens may help to protect other membrane lipid and pro-
tein components from oxidative damage [8]. The acyl chain at sn-2 of
plasmalogens is typically enriched in bioactive polyunsaturated fatty
acids (PUFA), such as arachidonic acid (AA) and docosahexaenoic acid
(DHA). Plasmalogens thus serve as reservoirs of PUFA [9] and are
enriched in lipid-raft domains of cellmembranes,which are hubs of signal
transduction [10].
In mammals, lysoplasmalogens are formed from plasmalogens by the
action of calcium-independent PLA2 (iPLA2) enzymes, which cleave the
acyl chain at sn-2 to release a free fatty acid [11]. A number of iPLA2 en-
zymes, including those from alveolar cells [12] and macrophages [13],
Fig. 1. Cartoon of the LpYhhN-TEV-GFP-8xHis fusion protein.
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signals [11]. At submicellar concentrations, lysoplasmalogens affect the
dynamics of cell membranes by increasing membrane ﬂuidity [14]. They
have speciﬁc effects on several transmembrane proteins, such as inhibi-
tion of cholinergic signal transduction [15], inhibition of Na-K-ATPase
[16], and activation of cAMP-dependent protein kinase C [17].
Lysoplasmalogens also serve as self antigens that stimulate invariant nat-
ural killer T cells in the thymus [18]. Due to their amphiphilic nature,
lysoplasmalogens can lyse cell membranes if present at high enough
levels [19,20]. Thus, lysoplasmalogens are normally maintained at very
low levels in cells [21].
Lysoplasmalogens can be converted back into plasmalogens by a
coenzyme A-independent transacylase, which re-acylates sn-2 in a pro-
cess referred to as “remodeling” [22]. Alternatively, lysoplasmalogens
can be further broken down by phospholipases C and D [23,24], or by
lysoplasmalogenase [25]. Lysoplasmalogenase (EC 3.3.2.2; EC 3.3.2.5)
catalyzes hydrolysis of the vinyl ether linkage at sn-1 to release a fatty
aldehyde and glycerophospho-ethanolamine (or choline) [25–28].
The enzyme is highly speciﬁc for glycerophospholipids containing a
vinyl-ether linkage at sn-1 and a hydroxyl (lyso) at sn-2, and acts
with nearly equal efﬁciency on ethanolamine and choline classes
[28]. Lysoplasmalogenase has been proposed to maintain lyso-
plasmalogen at low levels, to prevent toxicity [27,28].
In previous studies, we puriﬁed lysoplasmalogenase from rat liver
microsomes and identiﬁed the gene as TMEM86B [27,28], which en-
codes a 226 amino acid protein with eight predicted transmembrane
helices and previously unknown function [28]. TMEM86B is a member
of the larger YhhN family of proteins which are present in 138 species
of eukaryotes and 1205 species of bacteria, including many that are
human pathogens. Interestingly, many of the bacteria that encode a
YhhN family protein do not contain endogenous plasmalogens. Anaero-
bic bacteria contain relatively high amounts of plasmalogens, which are
synthesized by a pathway that is very different from the aerobic path-
way used in eukaryotes. However, aerobic and facultative anaerobic
bacteria have lost the capacity to synthesize plasmalogens and thus do
not contain them [1].
Given that the mammalian YhhN protein is a lysoplasmalogenase, it
seemed paradoxical to us that many of the aerobic bacteria that encode
a YhhN gene, such as Legionella pneumophila and Mycobacterium
tuberculosis, do not contain endogenous plasmalogens. It thus
seems likely that either the bacterial YhhN proteins hydrolyze
other types of lipids or else act on lysoplasmalogens derived from
host cells. L. pneumophila is a Gram-negative intracellular pathogen
that is the cause of Legionnaire's disease, a severe form of pneumonia
[29]. The bacteria replicate inside single cell protozoa, such as amoe-
ba. When contaminated water droplets contact human lung the bac-
teria enter into and replicate inside lung macrophages and alveolar
cells. To aid their survival, the bacteria orchestrate the development
of a specialized membrane-bound compartment, the Legionella con-
taining vacuole (LCV), which protects the bacteria from lysosomal
degradation and facilitates nutrient uptake [30,31]. The LCV mem-
brane is derived in part from membrane lipids of the host plasma
membrane and endoplasmic reticulum [32]. The processes involved in
LCV membrane development and in the interchange of biomolecules be-
tween bacteria and the host, are not well understood butmay involve the
action of bacterial phospholipase enzymes acting on host phospholipids.
Indeed, L. pneumophila encodes at least 14 different phospholipase A
enzymes, some of which have activity on lysophospholipids. These phos-
pholipases have been studied using ester-linked substrates [33], but
plasmalogen or lysoplasmalogen substrates have not been tested.
To test the hypothesis that L. pneumophila contains a lyso-
phospholipase that is active on lysoplasmalogens, we cloned the
Lpg1991 gene that encodes a YhhN family protein (hereafter referred
to as LpYhhN), and expressed it as a GFP fusion protein in Escherichia
coli. Both the fusion protein and the LpYhhN protein released after pro-
tease treatment exhibit abundant levels of lysoplasmalogenase activity.The substrate speciﬁcity and physical-chemical properties of the
LpYhhN fusion protein and the puriﬁed LpYhhNprotein are very similar
to those of mammalian TMEM86B. This work is to our knowledge the
ﬁrst to demonstrate a biochemical activity for a bacterial YhhN protein.
The work is also the ﬁrst to identify a bacterial lysophospholipase that
catalyzes hydrolysis of the vinyl ether bond of lysoplasmalogen.
2. Experimental procedures
2.1. Chemicals and materials
Porcine brain ethanolamine lysoplasmalogen (850095), Porcine
heart L-α phosphatidylcholine (840052), 1-O-1′-(Z)-octadecenyl-2-hy-
droxy-sn-glycero-3-phosphocholine (852465), 1-(1′-(Z)-octadecenyl)–
sn-glycerol (791459), sphingomyelin, and lysophosphatidic acid
were from Avanti Polar lipid, Inc (Alabaster, AL). Bovine brain phos-
phatidyl ethanolamine (356) was from Doosan-Serdary Research
Laboratories (Ontario, Canada). Yeast alcohol dehydrogenase
(LS001070) was fromWorthington Biochemical Corporation (Lake-
wood, N.J.). TRIS base, KCl, NaCl, HEPES, mannitol and sucrose were
reagent grade from SigmaAldrich Chemical Co. (St. Louis, MO). Dodecyl
maltoside was from Inalco Biochemicals (San Luis Obispo, CA). The
nickel afﬁnity columns were from GE Healthcare (His trap TM HP 17-
524701). The FPLC system was from GE-Healthcare Bio-Science Corp.
(Piscataway, NJ). The Amicon Ultra Centrifugal ﬁlter units (4 ml)
(10,000molecular weight cutoff) were fromMillipore Corporation (Te-
mecula, CA). The AcTEV Protease kit was from Invitrogen, (12575-015);
this AcTEV protease contains a poly Histidine tag at its N-terminus.
2.2. Construction of the plasmid for LpYhhN expression
The LpYhhN gene encoding the LpYhhN protein was PCR ampliﬁed
with Pfu Turbo DNA polymerase (Stratagene) from genomic DNA
from L. pneumophila strain ATCC 33152D-5 Philadelphia-1. The forward
primer was 5′-GCGCCATATGACTTATTCTTTTTCCAAACC-3′ and the re-
verse primer was 5′-GCGCGGATCCATCCCCTTCTTCATATAATCTG-3′
(NdeI and BamHI restriction sites are underlined). The resulting PCR
product was puriﬁed (Qiagen PCR puriﬁcation kit), and digested with
NdeI and BamHI restriction enzymes (New England Biolabs). After a sec-
ond PCR puriﬁcation step, the digested PCR productwas ligated into the
pWaldo-GFPd vector, also digested with NdeI and BamHI, using the
Quick Ligation kit (New England Biolabs), and transformed into chemi-
cally competentDH5α E. coli cells. DNA sequencing of the resultingplas-
mid revealed that the genewas identical to LpYhhN (GenBank accession
number AAU28060.1) with the exception of a single nucleotide position
resulting in a GAA codon instead of AAA at amino acid position 214,
which results in a K214E substitution in the protein. The resulting plas-
mid expressed the LpYhhN protein as a C-terminal GFP-8xHis fusion
with an intervening site for cleavage by TEV protease [34]. After cleav-
age with TEV protease the protein will have an extra GSENLYFQ se-
quence at the C-terminus (Fig. 1).
2.3. Overexpression of LpYhhN fusion protein
The plasmid encoding the LpYhhN-GFP fusion protein was trans-
formed into C43 (DE3) cells, and grown in 6 × 1 L cultures in 75%
Luria broth/25% Terriﬁc broth (TB) containing 50 μg/ml kanamycin, in
3 L bafﬂed ﬂasks at 170 rpm and 37 °C. When the OD600 reached 0.3–
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with 0.7mMisopropyl-Β-D-thiogalactoside (IPTG). Cellswere shaken at
170 rpm at 30 °C overnight (17 h), cooled to 2 °C on ice, and harvested
by centrifugation at 8000 ×g for 10 min. Cells were washed once in 10
times the pellet volume at 0 °C in Buffer A (150 mM NaCl, 15 mM
Tris–HCl, 15 mMNaH2PO4, 0.75 mMDTT, pH 7.9), and stored as pellets
at−80 °C.2.4. Cell lysis and subcellular fractionation
The cell pellet (about 8 gmwetweight) from each 1 L of culture was
suspended in 40 ml Buffer A, to which 100 U/ml DNase I and 1 mM
MgCl2 were added. Cells were passed through a French press twice
at 15,000 p.s.i. at 4 °C. The resulting lysates were centrifuged at
20,000 ×g at 4 °C for 20min to remove the unbroken cells. The superna-
tants containing themembranes were centrifuged at 130,000 ×g at 4 °C
for 55min. The translucent pellets, which contained 28mg of protein as
determined by Bradford assay [35], were resuspended in 4 ml of Buffer
A using a dounce homogenizer. About 220 μl of DDM (20% stock in
water)was addeddropwise to aﬁnal concentration of 1.0%, and the sus-
pensions were stirred occasionally for 30 min. The solubilized mem-
branes were centrifuged at 130,000 ×g for 1 h to remove insoluble
material.2.5. Partial puriﬁcation of the LpYhhN fusion protein from 1 L of cell culture
A 1 ml nickel column (GE Healthcare) charged with 0.1 M nickel
sulfate was equilibrated in Buffer B (300 mM NaCl, 50 mM
NaH2PO4, 10 mM imidazole, 0.1% DDM, pH 7.9). 10 ml of solubilized
membranes were loaded onto the column at 0.2 ml/min at 2 °C. The
column was washed with 15 ml of Buffer B at 0.2 ml/min, and the
protein was eluted by a gradient from 10 to 300 mM imidazole in
Buffer B over 20 ml at 0.14 ml/min. One-milliliter fractions were
assayed for lysoplasmalogenase activity and total protein. Fractions
containing activity were concentrated using Amicon centrifugal ﬁl-
ter units (10 kDa MWCO) that had been equilibrated with Buffer A
containing 0.1% DDM. Portions of the concentrated fractions were
stored at−20 °C after an equal volume of glycerol was added, to sta-
bilize the activity at – 20 °C [28]. Other portions were treated with
TEV protease to release the LpYhhN from the fusion protein, as de-
scribed below.2.6. Puriﬁcation of un-tagged LpYhhN from the LpYhhN-GFP fusion protein
The preparation and partial puriﬁcation of LpYhhN-GFP fusion pro-
tein from 1 L of cells described above was scaled up to process protein
from 3 L of culture. The cells were lysed by French press, membranes
were isolated by differential centrifugation and solubilized as described
above. The 120,000 ×g supernatant containing solubilized membranes
was applied to a 5 ml nickel column and the fusion protein was eluted
with an imidazole gradient. Three enriched 1.5 ml fractions from the
nickel column were pooled and concentrated to 800 μl. For cleavage
with TEV protease, the 4ml reaction included 1.24mgLpYhhN-GFP pro-
tein from the nickel column, 1.0 mM DTT, 0.1% DDM, 50 mM Tris–HCl,
pH 8.0, 0.5 mM EDTA, and 1167 U of TEV protease (Invitrogen 12575-
015). The reaction contents were gently mixed for 36 h at 0 °C. Aliquots
were retained for activity and gel analyses. The remainder (3500 μl)was
loaded on to a 1 ml nickel column at 0.02 ml per minute, and the ﬂow
through containing un-tagged LpYhhN protein was concentrated. Ali-
quots were made 50% with glycerol and stored in small aliquots at
−20 °C for kinetic analyses. Other aliquots were treated with 5 x load-
ing buffer for analyses on 11% PAGE gels. The GFP-His protein and the
TEV protease (with His tag) were eluted late in a 20 ml gradient of
10 mM – 300 mM imidazole in buffer B.2.7. Lipid substrates
Aqueous suspensions of lipid substrates were prepared about every
3 days from stock solutions stored in chloroform/methanol 2/1 (vol/vol)
at −20 °C as previously described [28]. For a portion of the experi-
ments shown in Fig. 6 (as indicated in the legend), the choline
lysoplasmalogen substrates were prepared in liposomes at 3 differ-
ent molar ratios of the lysoplasmalogen to the diradyl phospholipids.
Chloroform/methanolic solutions of choline lysoplasmalogen, bo-
vine brain glycerophosphoethanolamine, and 1-oleoyl-2-linoleoyl-
sn-glycero-3-phosphocholine were mixed in the molar ratios of 5%,
47.5%, 47.5%, respectively, 10%, 45%, 45%, respectively, and 20%,
40%, 40%, respectively. The mixtures were dried as a thin ﬁlm in glass
conical tubes under Nitrogen gas. 70 mM glycyl glycine-NaOH
(pH 7.1) was added to make aqueous suspensions of between 0.5 and
2 mM with respect to the choline lysoplasmalogen. The mixtures were
vortexed and sonicated four times for 15 seconds. The liposomes,
which were turbid, were maintained at 2 °C.
2.8. Coupled enzyme assay for lysoplasmalogenase activity (Assay 1)
A coupled enzyme assay using yeast alcohol dehydrogenase (ADH)
was performed as described previously [27,36,37]. Brieﬂy, the fatty
aldehyde that is released by hydrolysis of lysoplasmalogen is re-
duced to an alcohol by ADH in a reaction that is coupled to oxidation
of NADH to NAD+, which is monitored by loss of signal at 340 nm for
NADH. The standard reaction mixture (0.52 ml) contained 70 mM
glycylglycine-NaOH (pH 7.1), 1 mM DTT, 0.20 mM NADH, 0.52 mg
(130 IU) of yeast alcohol dehydrogenase, 220 nmol of lyso-
plasmalogen substrate, and between 1 and 20 μg of LpYhhN enzyme,
depending on the speciﬁc activity of the fraction. For determining
the pH optimum, the buffers in the coupled enzyme assay included
80 mM glycyl-glycine (NaOH) for pH 6.3 to 7.4, or 80 mM Tris–HCl
for pH 7.2 – 8.5. A unit of lysoplasmalogenase activity is deﬁned as
one nmol/min.
2.9. Lipid extraction, TLC, and phosphorus analysis assay for
lysoplasmalogenase activity (Assay 2)
The TLC assay was performed as described previously [27]. Brief-
ly, a separate reaction mixture was prepared for each time point in
conical glass test tubes with ground glass stoppers. The 2 ml reaction
mixtures were the same as described above for the coupled enzyme
assay, except that alcohol dehydrogenase and NADH were omitted,
and fatty acid-free BSA was included (0.43 mg/ml). The reactions
were stopped after 5 and 10 min by addition of 12 ml of chloro-
form/methanol (2/1, v/v) [38]. Following vigorous mixing, the lipid
and aqueous phases were separated, and lysoplasmalogen (lower
phase) and glycerophosphoethanolamine (upper phase) were each
concentrated and run on TLC plates to separate and identify the lipids
or water soluble components [39]. The glycerophosphoethanolamine
and lysoplasmalogen spots were quantiﬁed by phosphorus assay [40].
2.10. SDS–PAGE analysis of the partially puriﬁed proteins
Sufﬁcient 5× loading buffer was added to each puriﬁed sample to
obtain ﬁnal concentrations of 40 mM Tris–HCl pH 6.8, 10% glycerol,
2.4% SDS, 50mMdithiothreitol, and 0.001% bromophenol blue. Samples
were incubated at 40 °C for 30 min prior to loading onto the gel. In the
experiment of Fig. 5, the samples in lanes 1 and 3were incubated at 40 °C
for 30 min, and the samples in lanes 2 and 4 were heated to 95 °C for
4min. The fractions were analyzed using 11% or 12% gels using Tris–gly-
cine buffer and Laemmli procedure [41]. GFP-containing protein frag-
ments were visualized under UV-light using a Biorad imager. Protein
bands were visualized with Coomassie stain. Protein concentrations
were determined by the Bradford procedure [35].
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3.1. Overview of YhhN family proteins
The current Pfam database, version 27.0 [42], lists 1531 different pro-
tein sequences, from 1341 different species, that are considered to be
YhhN family proteins based on sequence homology. A total of 1322 of
these are from bacteria (1205 species) and 206 are from eukaryotes
(138 species). Humans andmost other mammals for which complete se-
quence information is available have twoYhhN family proteins,which are
TMEM86B (known to encode lysoplasmalogenase) and TMEM86A (un-
known function) in human. Among model organisms, YhhN family pro-
teins are found in Mus musculus (2 proteins), Xenopus laevis (2
proteins), Drosophila melanogaster (2 proteins), and Caenorhabditis
elegans (1 protein). Fungi tend to have only one YhhN family member.
The greatmajority of bacterial species that encode a YhhN protein encode
only one.
All of the YhhN family proteins tend to be from200 to 240 amino acids
in length and contain about eight transmembrane helices, as predicted
fromhydropathy plot analysis [43,44]. Fig. 2 shows a sequence alignment
of six different YhhN proteins, including four from bacteria (E. coli,Myco-
bacterium tuberculosis, L. pneumophila, and Burkholderia multivorans), and
TMEM86A and TMEM86B from human. All of these proteins, except for
the one from E. coli, are predicted to have their N-and C-termini facingIN           --------
ECOLI    -----------------------MLWSFIAVC
MYCTU    --------------------------------
BURKM    ---------MLA----TLPATYRRLCPLAVAA
LP   ---------MT----YSFSKPVSWVF--LFTA
TMEM86A  ---------MVSPV-TVVKSEGPKLVPFFKAT
TMEM86B  MDAGKAGQTLKTHCSAQRPDVCRWLSPFILSC
--TM2--------- IN     ------TM
ECOLI    TLLLLLLLAWQAPMF----DAISYLVLAGLCA
MYCTU    ---SM-AVLLAAAAVAHPIGRERRWLVPALLL
BURKM    ---AM-GILLLAAGSTLRAPRERAWLVAALAA
LEGPN    PIVCLIVGVFRTSLS----SSAKILLILALVF
TMEM86A  PIFCLWLFLLAHGLGFLLAHPSATRIFVGLVF
TMEM86B PVLCLAGFLWVMSPS----GGYTQLLQGALVC
:                    :  .*  
-------- IN  ----------TM5-----
ECOLI    LLYTIYFASQMTLSF--FWP--LPLVL-LVLG
MYCTU    LCFIGALLPLARQAAPSRGRVAAVVAMCVASA
BURKM    LCYCAIFLRW--RARPHGWRVAALVVLWIAAP
LEGPN    CFYITLFLKSFEFNRLHL-F--YYLPI-FLFM
TMEM86A MFYASAFG----MQPLAL-R--TGLVM-AALS
TMEM86B  LLYVWAFG----FSPLQP-G--LLLLI-ILAP
:   :                 : :     
------- IN        -------
ECOLI    VMVWLAGE-------LWFFRPTAPALSAFVGA
MYCTU    AMVCTALLA--------RL----PTIWTAVGA
BURKM    AMASFALAA--------DT----RAPLVAIGS
LEGPN   LMVFSAFQV--------KK----ETLTISSGA
TMEM86A  FMGWRAMAGLRLAGADWRW----TELAAGSGA
TMEM86B  AMLWRGLAQ---------------GGSAGWGA
*   .                        *:
--TM8--------- IN          
ECOLI    CYFAGHFLIVRSLYL--------------
MYCTU    SYAAAEILITAGFFFGREVPDNAAAPTDS
BURKM    LYALAQVVIVTGVFHETIARSVRP-----
LEGPN    TYYVAQFLLTFGLVRLYEKGG--------
TMEM86A TYYVAQMLVALSAVESREPVEHYRLTKAN
TMEM86B  TYYAAQLLITLSALRSPVPKTD-------
*  ...::. .
Fig. 2.Multiple-sequence alignment of YhhN proteins. The alignmentwas performed using Clus
tuberculosis (MYCTU), Burkolderia multivorans (BURKM), Legionella pneumophila (LP), and Hom
predicted by HMMTOP [44], are shaded in grey for each protein, with the consensus numbering
ment. “In” refers to cytoplasmic side, and “out” refers to non-cytoplasmic side. The predicted to
out). The shaded areas showing the predicted locations of helices TM1 and TM2 for TMEM86A
HMMTOP did not match the consensus. Highly conserved amino acids that are putative activethe cytoplasm. The core regions of these proteins exhibit about 30%
pairwise sequence identity with one another. TMEM86A and TMEM86B
from humans are 39% identical over the regions from amino acids 25–
223 and 15–230, respectively.
Rather strikingly, the sequence alignment reveals a number of highly
conserved amino acid residues of the types that are capable of performing
active site chemistry. In TMEM86B, these residues are Lys-53, Asp-88, His-
108, Ser-182, and Tyr-206. All of these residues are located on predicted
transmembrane helices and most are embedded within noticeably con-
served regions of the protein. In an alignment of 24 YhhN family proteins
from version 17.0 of the PANDIT database [46], Gly-174, Ser-182, and Tyr-
206 near the C-terminal end of TMEM86B are all completely invariant.
Lys-53 is highly conservedbut also present asGln (2 proteins), Arg (2 pro-
teins), or Leu (1 protein). Asp-88 is present in 23 proteins as Asp and in
one protein as His. His-108 is highly conserved but also present as Gln
(4 proteins), Tyr (1 protein), and Pro (1 protein). In summary, sequence
analysis of the YhhN family indicates a protein of about 220 amino
acids, 8 transmembranehelices, anN-in, C-in topology, and about 5highly
conserved amino acids that could form an active site.
3.2. Expression and puriﬁcation of YhhN protein from L. pneumophila
The goal of this workwas to clone, express, and purify a bacterial ho-
molog of TMEM86B to determinewhether othermembers of the YhhN----TM1----- OUT  ------
----LSAWLSVDASYRGPTWQRWVFKPL 33
-------------------MLQPAFKA- 8
ALLYGVSLAT------APYRGQFAAKA- 40
V-IYLVSL-S-----FIQYPATTVLKPI 38
C-VYFVLWLPS----SSPSWVSTLIKCL 45
C-VYFCLWIPE----DQLSWFAALVKCL 55
*  
3--------- OUT  ------TM4---
SLLGDALTLLPRQ--RLMYAIGAFFLSH 87
SATGDWLLAIPWWTWAFVFGLGAFLLAH 64
AVLGDVLLALPDSPFTFMGGLGAFLLTH 96
SLAGDVVLTLPFS-LQLELGIACFLLAH 93
SAVGDAFLIWQDQ-GYFVHGLLMFAVTH 104
SAVGDACLIWPA---AFVPGMAAFATAH 108
:  **           :  .:  *  :*
-------- OUT  --------TM6--
ALLLAIIWTRL--EEYRWPICTFIGMTL 140
GLLVW-FWPHLGKDNLTIPVTVYIVALS 123
AFYVA-FLPHLGA--LAVPVAVYMLVLV 151
GFAAFTMI-PY-LGNLLIPVMIYFCVLM 147
GLCYALLYPCL-SGAFTYLVGVYVALIG 155
GPYLSLVLQHL-EPDMVLPVAAYGLILM 159
.     .            :  :     
-TM7-------- OUT    -----
SLLFISNFVWLGSHYRRRFRADNAIAAA 193
VCFAASDSMIGIGRFILGNEALAVPIWW 171
LIFVGSDTLIGVERFLGGFPGIGPAIWA 199
LFFLISDLTLALNLFIYTQADVRIFVMF 195
LFFIISDLTIALNKFCFPVPYSRALIMS 211
LLFTLSDGVLAWDTFAQPLPHAHLVIMT 204
 :  *:       :             
     
208
200
223
216
240
226
tal Omega [45]. Sequences are, from top to bottom, Escherichia coli (ECOLI),Mycobacterium
o sapiens (TMEM86A and TMEM86B). The location of transmembrane helices, primarily as
of the helices and predicted In/Out topology of the loop regions indicated above the align-
pology of the E. coli protein is reversed relative to the others (it is predicted to be N-out, C-
, and TM3-TM5 of TMEM8B, used information from TMHMM [43], as the predictions from
site residues are indicated in magenta.
Fig. 3. Puriﬁcation of LpYhhN-GFP by nickel chromatography. (A) Elution proﬁle showing
the lysoplasmalogenase activity (ﬁlled circles) and total protein (open circles) of each 1ml
fraction from the nickel column. (B) SDS–PAGE gel, 12%. Lane 1, MW standards; Lane 2,
DDM treated 130,000 ×g insoluble pellet (4 units); Lane 3, solubilized membranes
(130,000 ×g supernatant) (14 units); Lane 4, fractions 8–10 from the nickel column (37
units); Lane 5: fractions 11–14 from the nickel column (84 units). Each lane contained ap-
proximately 10 μg of total protein and the number of units indicated above in parentheses.
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teria, are also lysoplasmalogenase enzymes. We chose the YhhN-like
protein from L. pneumophila because of its importance as a human path-
ogen. The LpYhhN protein has 216 amino acids, eight predicted trans-
membrane helices, and 30% sequence homology with TMEM86B. All of
the highly conserved putative active site residues indicated above are
present as the consensus residue in LpYhhN. We cloned the gene into
a pWaldo-GFP expression vector that has been shown to be useful for
production of transmembrane proteins in E. coli [34]. PCR primers
were designed to insert the gene between the NdeI and BamHI restric-
tion sites, to express the protein as a C-terminal GFP-8xHis fusion. The
GFP allows each step of the protein expression and puriﬁcation to be
readily monitored by ﬂuorescence, the 8xHis tag allows the LpYhhN fu-
sion protein to be puriﬁed by nickel afﬁnity chromatography, and the
TEV site allows the tag to be removed with TEV protease.
The resulting plasmid was transformed into E. coli C43 (DE3) cells,
which have been shown to be useful for expression of
transmembrane proteins [47]. The cells were grown in 1 L cultures at
30 °C for 17 h post-induction. After re-suspending the cells in NaCl
Tris–phosphate buffer (pH 7.9), the lysate prepared by French Press in
the absence of detergent contained a total of 44,000 units (nmol/
min) of lysoplasmalogenase activity, as determined using our standard
enzyme-coupled assay that measures the fatty aldehyde released from
choline lysoplasmalogen substrate [28]. Importantly, cells with an
empty control vector grown under identical conditions yielded only
500 units of activity. Since the E. coli K12 strain, of which C43 is a deriv-
ative, encodes an endogenous YhhN family protein, it is possible that
the basal level of activity is due to E. coli YhhN. In any case, the fact
the induced cells contained dramatically higher levels of activity than
the control cells provides strong evidence that the observed activity is
due to LpYhhN-GFP.
Table 1 (Puriﬁcation 1) shows a summary of a puriﬁcation of
LpYhhN-GFP from 1 L of E. coli. Brieﬂy, the initial cell lysate was centri-
fuged at 20,000 ×g to remove unbroken cells, and the supernatant was
centrifuged at 130,000 ×g to pellet the cell membranes. The resulting
pellet ﬂuoresced with bluish-green color under UV light, consistent
with it containing high levels of LpYhhN-GFP. By contrast, a pellet pre-
pared from cells grown with empty control vector did not ﬂuoresce.
Pelleted membranes were resuspended in buffer, DDM was added to
1%, and the suspension was centrifuged at 130,000 ×g to remove insol-
uble material. The supernatant, whichwas thematerial loaded onto the
nickel column, contained 19,000 units of lysoplasmalogenase activity
and 23.1mg of total protein. At this stage, a faint band at 36 kDawas ev-
ident on a Coomassie-stained SDS–PAGE gel (Fig. 3B, lane 3).
After the nickel column, analysis of each 1 ml fraction for lyso-
plasmalogenase activity resulted in two overlapping peaks (Fig. 3A),
centered on fractions 8–10 (Peak 1) and 11–14 (Peak 2). FractionsTable 1
Puriﬁcation of LpYhhN-GFP from 1 L (Puriﬁcation 1) and LpYhhN from 3 L (Puriﬁcation 2) of E
Puriﬁcation steps Volume (ml) Prot
(mg
Puriﬁcation 1: starting with 1 L of cells
1. Lysate from French press 35 800
2. 24,000 ×g supernatant (membranes and cytosol) 70 58
3. 130,000 ×g (1st) membrane pellet, solubilized with DDM 9.2 28.8
4. 130,000 ×g (2nd) pellet (insoluble membrane components) 2.8 4.86
5. 130,000 ×g (2nd) supernatant (solubilized membranes) 10 23.1
6a. His fractions 8–10 2.1 0.38
6b. His fractions 11–14 2.8 0.19
Puriﬁcation 2: Starting with 3000 ml of cell culture (80,000 units)
6. His fractions 17–19 4.5 1.2
7. TEV protease mixture 4.0 N.D.
8. 2nd His column ﬂow-through during enzyme addition,
concentrated
3.5 concentrated
to 900 μl
0.26
Lysoplasmalogenase activity wasmeasured by the coupled enzyme assay as described in the Ex
N.D. = not determined.from each peak were pooled separately and concentrated. Peak 2
contained 1,445 units of activity, or 3.3% of the total from the lysate,
and Peak 2 contained 1,621 units, which was 3.7% of the total. SDS–scherichia coli C43(DE3) cells.
ein
/fraction)
Units (nmol/min/fraction) Speciﬁc activity
(nmol/min/mg)
Puriﬁcation
(fold)
Recovery
(%)
44,000 55 1.0 100
15,600 269 4.9 35.5
16,274 565 10.3 37
1,419 292 5.3 3.2
19,000 823 15 43
9 1,445 3,715 67.5 3.3
2 1,621 8,443 153.5 3.7
5,230 4,350 79.2 6.5
4,800 N.D. N.D. N.D.
6 1,862 7,000 127.3 2.3
perimental Procedures section. Protein concentrationswere determined by Bradford assay.
Fig. 5. LpYhhN-GFP and LpYhhNprotein form aggregates in SDS gel samples heated to 95 °C.
Each lane of the 11% SDS–PAGE gel was loaded with approximately 15 μg of total protein.
Lanes 1 and 6 contain MW standards. Lanes 2 and 3 contain LpYhhN-GFP protein from the
ﬁrst nickel column, and lanes 4 and5 contain the un-tagged LpYhhNprotein from the second
nickel column. The samples in lanes 2 and 4were heated to 40 °C after adding the SDS load-
ing buffer, while the samples in lanes 3 and 5 were heated to 95 °C. Band a in lane 2 is the
LpYhhN-fusion protein. Band b in lane 4 is the un-tagged LpYhhN protein. Notice that
heating to 95 °C (lanes 3 and 5) leads to disappearance of distinct bands for LpYhhN-GFP
and LpYhhN, presumably due to formation of aggregates. This does not happen for most of
the E. colimembrane proteins that are seen in the background (compare lanes 2 and 3).
However, a similar phenomenon with membrane proteins has been noted previously [48].
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5). Although this M.W. is considerably smaller than that predicted from
the amino acid sequence of LpYhhN-GFP (46 kDa), this behavior is not
uncommon for integral membrane proteins [34]. Moreover, as shown
in Fig. 4b, lane 4, the 36 kDa band is strongly ﬂuorescent under UV
light, indicating that it indeed contains GFP. At later stages of the puriﬁ-
cation, mass spectrometry analyses of a trypsin digest of material from
the 36 kDa band conﬁrmed that the protein contains LpYhhN (Supple-
mentary Fig. 1). Importantly, the proteomics analysis identiﬁed a pep-
tide from the N-terminus of LpYhhN, indicating that the protein in the
36 kDa band contains the full-length LpYhhN, and not an N-terminal
truncation. As will be shown below (Fig. 4), TEV cleavage separates
this band into GFP, which runs on the SDS–PAGE at its predicted mass
of 20 kDa and un-tagged LpYhhN, which runs at 18 kDa, smaller than
its predicted mass of 24.5 kDa. Rat TMEM86B also runs on an SDS–
PAGE gel at a smaller MW than predicted, at 18–19 kDa. [28]. Based
on all of these considerations, we conclude that the 36 kDa band is the
LpYhhN-GFP fusion protein.
We also note that after mixing the protein with the SDS–PAGE
loading buffer, heating of the samples to the usual 95 °C resulted in
complete disappearance of the 36 kDa band and of the18 kDa band,
presumably due to the formation of aggregates (Fig. 5). Thus, all gel
samples were heated to only 40 °C for 30 min. This behavior is also
seen for TMEM86B [28], as well as for certain other transmembrane
proteins [34].
3.3. Cleavage of the LpYhhN-GFP with TEV protease and further puriﬁcation
of LpYhhN
The addition of TEV protease to the protein from the nickel column
produced the expected cleavage pattern (Fig. 4A, lane 5). The band at
36 kDa corresponding to LpYhhN-GFP was depleted (compare lanes 4
and 5), and new bands appeared for GFP (20 kDa), LpYhhN (18 kDa),
and TEV protease (26 kDa). Imaging of the gel under UV light conﬁrmed
that the bands corresponding to GFP and LpYhhN-GFP were ﬂuorescent
while bands corresponding to TEV and LpYhhN were not (Fig. 4B). A
western blot probingwith antibodies to GFP further conﬁrmed the pres-
ence or absence of GFP for each band (Fig. 4C). Since both the GFP and
TEV contained histidine tags, a “reverse” nickel column was performed
to separate the un-tagged LpYhhNprotein (Fig. 4A, lane 7) from theGFP
and the TEV protease (Fig. 4A, lane 8). The ﬁnal puriﬁed LpYhhN protein
is also shown in Fig. 5, lane 4 (18 kDa). The ﬁnal yield of the un-tagged
LpYhhN protein from 3 L of E. coliwas 270 μg and 1,862 units (Table 1,
Puriﬁcation 2). This was 2.3% of the total from the starting cell lysate.
3.4. Enzyme analysis
As was seen previously for TMEM86B, both un-tagged LpYhhN
and the LpYhhN-GFP fusion required the continuous presence of
0.1% DDM or 2–4 mM diradylglycerophospholipid for maintenanceFig. 4. SDS–PAGE of the LpYhhN-GFP TEV cleavage. (A) Coomassie-stained 11% SDS–PAGE gel.
membranes (130,000×g supernatant). Lane 4, pooled fractions from thenickel column. Lane 5, s
nickel column after TEV treatment. The band at 18 kDa is the LpYhhN protein. Lane 8, imidazol
(Invitrogen, 30 U). (B) The same gel as panel A, but visualized under UV-light (prior to staining
ferred to PVDF membrane and probed with antibodies against GFP. Each gel lane contained apof activity at 4 °C. For storage at−20 °C, the presence of 50% glycerol
or 2–4 mM diradylglycerophospholipid was also required.
Typical of enzyme catalyzed reactions, the reaction velocity
depended on the amount of enzyme added (data not shown), and
heating the enzyme to 95 °C for 3min resulted in complete loss of ac-
tivity (Table 2). At constant enzyme concentration, the amount of
product formed increased linearly with time for more than 10 min
(Table 3). These observations indicate that the observed activity is due
to the puriﬁed protein. The reaction velocity as a function of substrateLane 1, MW standard. Lane 2, DDM treated Escherichia colimembranes. Lane 3, solubilized
ample from lane4 treatedwith TEV protease. Lane 6, empty. Lane7,ﬂow-through from the
e-eluted fraction showing bands for TEV (26 kDa) and GFP (20 kDa). Lane 9, TEV protease
with Coomassie) to show GFP-containing bands. (C) A similar gel as panels A and B trans-
proximately 10 μg of total protein.
Table 2
Effects of heat and various compounds on LpYhhN-GFP lysoplasmalogenase activity.
Treatment % of control activity Reaction velocities were determined by the coupled enzyme assay. The substrate was 450 μM
ethanolamine lysoplasmalogen. A control reaction without enzyme yielded 8 nmol of aldehyde
per minute per ml. One microgram of LpYhhN-GFP protein from fractions 8–14 of the nickel
column was added to a 0.52 ml reaction. The standard deviation in parentheses was calculated
from three independent measurements.
None 100
Enzyme heated at 95 °C for 5 min 0
Addition of MgCl2 10 mM 75 (7)
Addition of EDTA 2 mM 100 (7.1)
Addition of lysophosphatidic acid 250 μM 100 (6.3)
Addition of PMSF 500 μM 100 (9.2)
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strates, is shown in Fig. 6 for the un-tagged LpYhhN protein. The curves
followed rectangular hyperbolas characteristic of the binding isotherm.
At the lower levels of substrate examined, 3, 6, and 10 µM , the rates of
activity fell along the curves shown in Fig. 6 (upper 2 curves). (Only the
10 μM velocity point is shown on the graph.) These lower concentra-
tions of substrate are probably below the CMC of lysoplasmalogen
under these conditions. The apparent Vmax values were 11 and 12
μmol/min/mg for ethanolamine and choline lysoplasmalogen sub-
strates, respectively. The apparent Km value for both substrates was
45 μM. The kinetic behavior of the LpYhhN-GFP fusion protein was
very similar (data not shown).
In the kinetic experiments described in the previous paragraph, the
lipid substratewas presented to the enzyme as a sonicated aqueous sus-
pension. To test if LpYhhN can also hydrolyze lysoplasmalogens embed-
ded within a lipid bilayer, substrates were presented to the enzyme as
components of liposomes. In these experiments, the fraction of
lysoplasmalogen relative to total phospholipid was varied from 5% to
20%. As can be seen in Fig. 6, LpYhhN was indeed able to hydrolyze
lysoplasmalogens when presented in liposomes, and at constant
lysoplasmalogen concentration, the velocity tended to increase as the
mole % of lysoplasmalogen increased.
Prior to puriﬁcation of un-tagged LpYhhN, several properties of
the enzyme in its GFP-tagged form were characterized (Table 2).
Addition of EDTA, sodium ﬂuoride, PMSF, phosphatidic acid,
lysophosphatidic acid, monoacylglycerophospho-choline, and
monoacylglycerophospho-ethanolamine to the reaction were test-
ed and found to have no effect. Addition of 10 mM Mg2+ lowered
the activity by 25%. The pH optimum of the LpYhhN-GFP enzymes
is between 6.5 and 7.0, which is similar to TMEM86B.
The experiments described to this point used an assay for
lysoplasmalogenase activity that detects the release of fatty aldehyde,
the reduction of which is coupled to the oxidation of NADH. To
further verify that the reaction being catalyzed is indeed that of a
lysoplasmalogenase, the LpYhhN-GFP enzyme-substrate mixture was
subjected to lipid extraction at various time points [38] followed by
TLC of the lipid fraction containing lysoplasmalogen, and the aqueous
fraction containing glycerophosphoethanolamine (Table 3). The spots
corresponding to lysoplasmalogen and glycerophosphoethanolamine
were scraped and quantiﬁed by phosphorus assay [39]. A 1:1:1 stoichi-
ometrywas observed between the amount of lysoplasmalogen that dis-
appeared, and the amounts of glycerophosphoethanolamine and of
aldehyde that were formed. These results are consistent with theTable 3
Quantitative correlation between substrate depletion and product formation in the LpYhhN lys
Time (min) Amount of product formed or substrate depleted (nmol/2 ml)
1-Alkenylglycero-phospho-ethanolamine depleted b
0 0
5 118 (13)
10 230 (21)
Concentration of ethanolamine lysoplasmalogen substrate was 400 μM. The enzyme source w
The reactions were run in duplicates, and the standard errors are in parentheses.
a Enzyme assay 1 (coupled enzyme assay) was used to determine rates.
b Enzyme assay 2 (determined by TLC assay described in the Experimental Procedures secticonclusion that the enzyme is cleaving the vinyl-ether bond at the sn-
1 carbon of lysoplasmalogen to release the expected products. TLC
plates for reactions with LpYhhN-GFP were essentially identical to
those performed with TMEM86B protein puriﬁed previously from rat
liver, suggesting that the two enzymes are catalyzing the same reaction.
To characterize the substrate speciﬁcity of the LpYhhN enzyme, reac-
tions were performed using other types of lipids as potential substrates,
including 1-alkenyl-glycerol, two plasmalogens (alkenyl-2-acyl-sn-
glycero-3-phospho-choline and -ethanolamine), the monoacyl
glycerophospholipids 1-acyl-sn-glycero-3-phospho-choline and
ethanolamine, and lysophosphatidic acid (1-acyl-sn-glycerol-3-
phosphatidic acid) (Table 4). None of these substrates yielded de-
tectable levels of product using either assay, suggesting that the hy-
drolytic activity of the LpYhhN-GFP protein is highly speciﬁc for the
vinyl-ether bond at the sn-1 and for a hydroxyl group at sn-2 posi-
tions, as is the case for the TMEM86B enzyme.
4. Discussion
4.1. The YhhN protein of L. pneumophila is a lysoplasmalogenase
Lysoplasmalogenase catalyzes the hydrolytic cleavage of the
vinyl ether bond of lysoplasmalogens to form a fatty aldehyde and
glycerophospho-ethanolamine (or -choline). In a previous study,
we puriﬁed the lysoplasmalogenase enzyme from rat liver micro-
somes, and identiﬁed the protein as TMEM86B [28]. TMEM86B is a
member of the larger YhhN family of proteins, which are present in
138 species of eukaryotes and 1205 species of bacteria, many of
which are known human pathogens, including M. tuberculosis,
L. pneumophila, Versinia pestis, and B. multivorans.
In this work, we asked if the YhhN proteins of bacteria, which are
about 30% identical in sequence to TMEM86B, also function as
lysoplasmalogenase enzymes, despite the fact that many of the bac-
teria that encode them do not contain endogenous plasmalogens. To
answer this question, we cloned and expressed the YhhN gene of
L. pneumophila as a GFP fusion protein in E. coli. The membranes
were isolated and solubilized and the LpYhhN-GFP protein was puri-
ﬁed by nickel chromatography, cleaved with TEV protease, and the
mixture was run over a second nickel column to isolate the un-
tagged LpYhhN protein. The results of the enzyme assays are clear:
both the LpYhhN-GFP fusion and the un-tagged LpYhhN protein ex-
hibit abundant levels of lysoplasmalogenase activity. This is to our
knowledge the ﬁrst demonstration of a biochemical activity for aoplasmalogenase reaction.
Aldehyde produced a Glycerophosphoethanolamine producedb
0 0
120 (6) 120 (11)
250 (17) 235 (19)
as 5 μg of LpYhhN-GFP from fractions 8–14 of the nickel column (Fig. 3, lanes 4–5).
on.)
Fig. 6. Lysoplasmalogenase reaction velocity as a function of substrate concentration. The
upper 2 curves show reactionswith lysoplasmalogen added as sonicated aqueous suspen-
sions. Substrates were choline-lysoplasmalogen (ﬁlled circles) or ethanolamine (open cir-
cles). The three lower curves, showreactions inwhich choline lysoplasmalogenwas added
as a component of liposomes, to mimic the conditions present in cell membranes; higher
levels of liposome substrates could not be used as the initial absorbance at 340 nmwas too
high (greater than 2.3) for accurate reading in the coupled enzyme assay. The molar % ra-
tios of choline lysoplasmalogen to phosphatidyl choline and phosphatidyl ethanolamine
were varied. The relative amounts of these lipids were 5%, 47.5%, 47.5% (open squares),
10%, 45%, 45% (ﬁlled triangles), and 20%, 40%, 40% (crosses), respectively. The 0.52 ml re-
actions contained 1.2 μg of the puriﬁed LpYhhN protein shown in Fig. 5, lane 4. Reaction
velocities were determined by the coupled enzyme assay, as described in the Experimen-
tal Procedures section. The plotted values are the mean of two independent measure-
ments that differed by less than 10%. The curves are representative of two separate
experiments performed on different days.
749M.S. Jurkowitz et al. / Biochimica et Biophysica Acta 1848 (2015) 742–751bacterial YhhN-like protein, and the ﬁrst bacterial enzyme found that
cleaves the vinyl ether bond of a lysoplasmalogen substrate.
4.2. The physical and chemical properties of the LpYhhN protein are similar
to TMEM86B
LpYhhN is an integral membrane protein of a similar size as
TMEM86B (216 vs. 226 amino acids). Sequence analysis predicts it to
have eight transmembrane helices. The hydrophobic properties that re-
quire 1% DDM for solubilization and the continued presence of DDM or
diradylglycerophospholipid formaintenance of activity are the same for
both proteins.
The pH optimum, apparent kinetic parameters, and substrate
speciﬁcities of LpYhhN are also very similar to those of TMEM86B.
The Vmax values of 11 and 12 μmol/min/mg for LpYhhNwith ethanol-
amine and choline lysoplasmalogen, respectively, are only slightly
lower than the corresponding values of 17 and 24 for TMEM86B.
Similarly, the Km value of 45 μM for LpYhhN with both substrates isTable 4
Substrate speciﬁcity of LpYhhN lysoplasmalogenase.
Velocity (nmol⋅min−1⋅ml−1)
Ethanolamine lysoplasmalogena 8.3 (0.8)
Choline lysoplasmalogena 8.1 (0.75)
Alkenyl glycerola 0
Ethanolamine plasmalogena 0
Choline plasmalogena 0
Monoacylglycerophospho-ethanolamineb 0
Monoacylglycerophospho-cholineb 0
Lysophosphatidic acidb 0
Substrate concentrations were 400 μΜ; 0.7 μg of LpYhhN fusion protein from fraction 8–
14 of the nickel column was added to 0.52 ml reaction cuvette. The reactions were run
in duplicates or triplicates, and the standard errors are shown in parenthesis.
a Enzyme assay 1 (coupled enzyme assay) was used to determine rates.
b Enzyme assay 2 (determined by TLC assay described in the Experimental Procedures
section).very close to Km value of 50 μM for TMEM86B. Like TMEM86B,
LpYhhN is highly speciﬁc for the sn-2-deacylated (lyso) form of
plasmalogen, and has no activity on the diradyl plasmalogens. The
requirement for an sn-2 hydroxyl in the substratemay also be impor-
tant mechanistically, as it has been suggested that it could partici-
pate directly in the hydrolysis reaction [25].
One notable difference between LpYhhN and TMEM86 was found.
Lysophosphatidic acid inhibits TMEM86B with a Ki of about 50 μM
[28] but does not inhibit LpYhhN, even at concentrations as high as
500 μM(Table 4).We do not at present understand the biological signif-
icance of this observation.
4.3. Could bacteria that do not contain endogenous plasmalogens or
lysoplasmalogens be exposed to them during an infection?
Anaerobic bacteria synthesize and contain plasmalogens in their
membranes, but aerobic and facultative anaerobic bacteria, such as
L. pneumophila and M. tuberculosis, do not [1]. The absence of
plasmalogens and lysoplasmalogens in many of the bacteria that
encode a YhhN gene is interesting and at ﬁrst appears paradoxical.
However, the host cells in which the bacteria reside, such as amoeba
(L. pneumophila) and lung macrophages (L. pneumophila and
M. tuberculosis), are known to contain abundant levels of plasmalogens.
Moreover, pneumocytes and surfactant have 12% and 4%, respectively,
of their phospholipids in the plasmalogen subclass [49–51].
While it is thus clear that plasmalogenswould be present in the cells
infected by L. pneumophila, the extent to which lysoplasmalogens could
accumulate is unknown. In mammals, lysoplasmalogens are formed
from plasmalogens by the action of calcium-independent PLA2 (iPLA2)
enzymes that remove the acyl chain at sn-2. Some of the mammalian
iPLA2 enzymes (group VI) are highly selective for plasmalogens
[52,53]. The iPLA2 enzyme present in macrophages [13] and type II
pneumocytes [12] is activated during certain physiological and
pathophysiological conditions [11]. Thus, during an infection with
L. pneumophila, lysoplasmalogens could potentially be released from
plasmalogens of host macrophages, pneumocytes, and surfactant.
It is also possible that plasmalogens could serve as substrates for one
ormore of themanybacterial phospholipaseA. Althoughwehave found
no studies in which plasmalogens or lysoplasmalogens were tested as
substrates for a bacterial phospholipase A, signiﬁcant sequence homol-
ogies exist between VipD, a patatin-like phospholipase (PLP) of
L. pneumophila, strain Philadelphia (AAU28879.1), and the mammalian
iPLA2 gamma enzymes (group VI) (NP_001242940.1), which hydrolyze
plasmalogens [52,53]. The homologous regions include the conserved
catalytic residues of iPLA2, including the GDSRG sequence, in which
the arginine is replaced by a lysine in VipD. VipD has phospholipase A
activity with diacyl glycerophospholipid substrates [34]; plasmalogen
was not tested as a substrate. If the VipD enzyme (and or other phos-
pholipases A) of L. pneumophila does have activity on plasmalogens, it
could conceivably provide a source of lysoplasmalogen for the bacteri-
um to encounter.
4.4. What is the biological role for a bacterial lysoplasmalogenase?
Although our data have not yet answered this question, LpYhhN
could conceivably serve to protect the bacteria from lysis by
lysoplasmalogen. Such a rolewould be analogous to lysophospholipases
of L. pneumophila that protect it from monoacyl glycerophospholipids
(monoacyl GPL) [54], and to mammalian lysophospholipases that
protect their cells from monoacyl GPLs [55]. The high Vmax and the
low Km of LpYhhN are compatible with a role for the enzyme in main-
taining lysoplasmalogens at low levels to prevent lysis of the bacterial
cytoplasmicmembrane. The CMC for lysoplasmalogens ranges from ap-
proximately 1 to 25 μM, depending on the length of the alkyl chain and
whether or not albumen is present [20]. If present at concentrations
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(hence their name).
L. pneumophila produces both secreted and cell associated
lysophospholipase activities with monoacyl GPL [54]. L. pneumophila
showed reduced growthwhen exposed to 50–200 μM lysophosphatidyl
choline (LPC), indicating that LPC is cytotoxic. Mutation of the gene for
the secreted lysophospholipase increased the sensitivity of the bacteria
to LPC. Conversely, overexpression of the secreted lysophospholipase
decreased the sensitivity of the bacteria to LPC. It was concluded
that the lysophospholipase served to protect the bacteria from
toxic effects of the lysolipid [54]. It must be emphasized, however,
that the lysophospholipase of this studywas secreted outside the bacte-
rial cell, whereas LpYhhNwould presumably remainmembrane bound.
How LpYhhN would come into contact with lysoplasmalogens remains
to be determined.
There are no studies on the effects of 1-alkenyl GPL (lysoplasmalogen)
on bacteria. However, the structures and physical properties ofmonoacyl
GPL and lysoplasmalogen are similar; they are both amphiphilic mole-
cules [14,20]. At levels below their CMC, monoacyl GPLs are able to
move across lipid bilayers and cell membranes [20]; these studies
have not been done with lysoplasmalogens yet. Both monoacyl GPL
and monoalkenyl GPL increase membrane ﬂuidity and disrupt lipid bi-
layers. Lysoplasmalogens, with their vinyl ether linkage at sn-1, cause
an even greater disturbance of bilayer structure than monoacyl GPL
[14]. Both of thesemono-radyl GPLs have been shown to lyse cell mem-
branes at levels near their CMCs [19,20].
4.5. Hydrolytic cleavage of a vinyl ether bond is a rare reaction in biology.
There is only one other enzyme-catalyzed reaction known in nature
that involves cleavage of a vinyl-ether bond. The reaction is catalyzed by
the bacterial enzyme isochorismatase, which cleaves isochorismate to
form pyruvate and 2,3-dihydroxybenzoate [56]. Isochorismatase is a
globular, water-soluble enzyme, with an α/β-type fold [57]. This con-
trasts markedly with lysoplasmalogenase, an α-helical transmembrane
protein. Thus, it is not likely that YhhN family proteins will bear any
structural resemblance to isochorismatase, despite the common chem-
istry of the reactions. Sequence comparisons reveal only a very short, 22
amino acid regionwith 23% identity between the two proteins, which is
unlikely to be statistically signiﬁcant, given the short length. The fact
that this region does not correspond to any of the conserved regions
containing putative catalytic residues of YhhN family proteins (Fig. 2),
or to the known catalytic residues of isochorismatase [57], further sug-
gests that the two proteins do not share a common fold or arrangement
of catalytic residues.
Terminology
Diradyl glycerophospholipids: phosphatidylcholine, 1,2-diacyl-sn-
glycero-3-phosphocholine, diacyl GPC; phosphatidylethanolamine,
1,2-diacyl-sn-glycero-3-phosphoethanolamine, diacyl GPE;
Plasmalogens include: plasmenylethanolamine, 1-alk-1′-enyl-2-
acyl-sn-glycero-3-phosphoethanolamine; plasmenylcholine, 1-alk-
1′-enyl-2-acyl-sn-glycero-3-phosphocholine.
Monoradylglycerophospholipids: lysophosphatidyl-choline or
ethanolamine are monoacylphosphatidyl-choline or ethanolamine,
monoacyl GPC, monoacyl GPE, or monoacylGPL (L, for lipid);
Lysophosphatidyl choline is also called LPC.
Lysoplasmalogens include: lysoplasmenylethanolamine, 1-alk-
1′-enyl-sn-glycero-3-phosphoethanolamine; lysoplasmenylcholine,
1-alk-1′-enyl-sn-glycero-3-phosphocholine.
Names of the gene and protein; LpYhhN protein is the namewe use
in this paper for the protein product of the Lpg1991 gene of
L. pneumophila, strain Philadelphia; LpYhhN fusion protein is the name
we use in this manuscript for the LpYhhN-GFP-8His fusion protein.
The gene product of Lpg1991 is also named Q5ZU17_LEGPH.Acknowledgments
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